<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04994509</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-412-5624</org_study_id>
    <nct_id>NCT04994509</nct_id>
  </id_info>
  <brief_title>Study to Assess Safety and Efficacy of Lenacapavir and Emtricitabine/Tenofovir Alafenamide for Pre-Exposure Prophylaxis in Adolescent Girls and Young Women at Risk of HIV Infection</brief_title>
  <acronym>PURPOSE 1</acronym>
  <official_title>A Phase 3, Double-Blinded, Multicenter, Randomized Study to Evaluate Safety and Efficacy of Twice Yearly Long-Acting Subcutaneous Lenacapavir, and Daily Oral Emtricitabine/Tenofovir Alafenamide for Pre-Exposure Prophylaxis in Adolescent Girls and Young Women at Risk of HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of lenacapavir (LEN) and&#xD;
      emtricitabine/tenofovir alafenamide (F/TAF) in preventing the risk of human immunodeficiency&#xD;
      virus (HIV) infection relative to the background HIV incidence rate.&#xD;
&#xD;
      The study will be conducted in 2 parts: a cross-sectional study (Incidence Phase) and a&#xD;
      double-blind, randomized study (Randomized Phase). The Incidence Phase will include initial&#xD;
      assessments that will provide an estimate of the concurrent background HIV incidence rate.&#xD;
      The Randomized Phase of the study will have a Blinded Phase, a LEN Open-label Extension (OLE)&#xD;
      Phase, and a Pharmacokinetic (PK) Tail Coverage Phase.&#xD;
&#xD;
      The primary objective for the Incidence Phase of this study is to estimate the HIV background&#xD;
      incidence rate. The primary objectives of the Randomized Phase of this study are to evaluate&#xD;
      the efficacy of LEN and F/TAF for HIV pre-exposure prophylaxis (PrEP) in adolescent girls and&#xD;
      young women (AGYW) at risk of HIV infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2021</start_date>
  <completion_date type="Anticipated">June 2027</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence Phase: Background HIV Incidence Reported Per 100-Person-Years (PY)</measure>
    <time_frame>At Screening</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Randomized Phase: HIV Incidence Reported Per 100-PY of Follow-up</measure>
    <time_frame>When all participants have a minimum of 52 weeks of exposure to study drug or permanent discontinuation, whichever occurs first (maximum approximately 3 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV Incidence Among Participants While Adherent to Study Drug</measure>
    <time_frame>When all participants have a minimum of 52 weeks of exposure to study drug or permanent discontinuation, whichever occurs first (maximum approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-Emergent Adverse Events</measure>
    <time_frame>When all participants have a minimum of 52 weeks of exposure to study drug or permanent discontinuation, whichever occurs first (maximum approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Clinically Significant Laboratory Abnormalities</measure>
    <time_frame>When all participants have a minimum of 52 weeks of exposure to study drug or permanent discontinuation, whichever occurs first (maximum approximately 3 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">5010</enrollment>
  <condition>Pre-Exposure Prophylaxis of HIV Infection</condition>
  <arm_group>
    <arm_group_label>Blinded Phase: LEN + Placebo-to-match (PTM) F/TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the following for at least 52 weeks:&#xD;
Subcutaneous (SC) lenacapavir (LEN) 927 mg every 26 weeks&#xD;
Oral PTM Emtricitabine/Tenofovir Alafenamide (F/TAF) once daily&#xD;
Oral LEN 600 mg on Days 1 and 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blinded Phase: LEN + PTM F/TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the following for at least 52 weeks:&#xD;
SC LEN 927 mg every 26 weeks&#xD;
Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily&#xD;
Oral LEN 600 mg on Days 1 and 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blinded Phase: Placebo LEN + F/TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the following for at least 52 weeks:&#xD;
SC placebo LEN every 26 weeks&#xD;
Oral F/TAF 200/25 mg once daily&#xD;
Oral PTM LEN on Days 1 and 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blinded Phase: Placebo LEN + F/TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the following for at least 52 weeks:&#xD;
SC placebo LEN every 26 weeks&#xD;
Oral F/TDF 200/300 mg once daily&#xD;
Oral PTM LEN on Days 1 and 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEN Open-Label Extension (OLE) Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After completion of the Blinded phase, participants will be offered entry into the LEN OLE Phase.&#xD;
Participants randomized to LEN will continue to receive SC LEN 927 mg every 26 weeks for a total of 2 doses.&#xD;
Participants randomized to F/TAF or F/TDF will receive SC LEN 927 mg on OLE Day 1 and OLE Week 26, and will also receive oral LEN 600 mg on OLE Days 1 and 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pharmacokinetic (PK) Tail Coverage Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At the completion of the LEN OLE phase, participants will transition into the PK Tail Coverage phase.&#xD;
Additionally, participants that either prematurely discontinue the study drug during the blinded phase or choose not to continue in the LEN OLE phase (if randomized to LEN in the blinded phase) or who discontinue the study drug in the LEN OLE phase are also eligible to transition to the PK Tail Coverage phase.&#xD;
Participants will receive oral F/TDF once daily for 78 weeks beginning 26 weeks after the last LEN injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Lenacapavir (LEN)</intervention_name>
    <description>Tablets administered orally without regard to food</description>
    <arm_group_label>Blinded Phase: LEN + PTM F/TDF</arm_group_label>
    <arm_group_label>Blinded Phase: LEN + Placebo-to-match (PTM) F/TAF</arm_group_label>
    <arm_group_label>LEN Open-Label Extension (OLE) Phase</arm_group_label>
    <other_name>GS-6207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous (SC) Lenacapavir (LEN)</intervention_name>
    <description>Administered via SC injections</description>
    <arm_group_label>Blinded Phase: LEN + PTM F/TDF</arm_group_label>
    <arm_group_label>Blinded Phase: LEN + Placebo-to-match (PTM) F/TAF</arm_group_label>
    <arm_group_label>LEN Open-Label Extension (OLE) Phase</arm_group_label>
    <other_name>GS-6207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F/TAF</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>Blinded Phase: Placebo LEN + F/TAF</arm_group_label>
    <other_name>Descovy®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F/TDF</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>Blinded Phase: Placebo LEN + F/TDF</arm_group_label>
    <arm_group_label>Pharmacokinetic (PK) Tail Coverage Phase</arm_group_label>
    <other_name>Truvada®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo SC LEN</intervention_name>
    <description>Administered via SC injections</description>
    <arm_group_label>Blinded Phase: Placebo LEN + F/TAF</arm_group_label>
    <arm_group_label>Blinded Phase: Placebo LEN + F/TDF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTM Oral LEN</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>Blinded Phase: Placebo LEN + F/TAF</arm_group_label>
    <arm_group_label>Blinded Phase: Placebo LEN + F/TDF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTM F/TAF</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>Blinded Phase: LEN + Placebo-to-match (PTM) F/TAF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTM F/TDF</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>Blinded Phase: LEN + PTM F/TDF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Incidence Phase&#xD;
&#xD;
               -  HIV-1 status unknown at initial screening and no prior human immunodeficiency&#xD;
                  virus ( HIV)-1 testing within the last 3 months&#xD;
&#xD;
               -  Sexually active (has had &gt; 1 vaginal intercourse within the last 3 months) with&#xD;
                  cisgender male individuals (CGM)&#xD;
&#xD;
          -  Randomized Phase&#xD;
&#xD;
               -  Negative fourth generation HIV-1 antibody (Ab)/antigen (Ag) test confirmed with&#xD;
                  central HIV-1 testing&#xD;
&#xD;
               -  Estimated glomerular filtration rate (GFR) ≥ 60 mL/min at screening&#xD;
&#xD;
               -  Body weight ≥ 35 kg&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Prior receipt of an HIV vaccine&#xD;
&#xD;
          -  Prior use of long-acting systemic pre-exposure prophylaxis (PrEP)&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Cisgender</gender_description>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Madibeng Centre for Research</name>
      <address>
        <city>Brits</city>
        <zip>2500</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MatCH Research Unit, Suite 1112, 11th Floor</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Setshaba Research Centre</name>
      <address>
        <city>Gauteng</city>
        <zip>152</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wits Reproductive Health &amp; HIV Institute (Wits RHI)</name>
      <address>
        <city>Johannesburg</city>
        <zip>2038</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Aurum Institute: Gavin J Churchyard Legacy Centre, Klerksdorp Clinical Research Centre</name>
      <address>
        <city>Klerksdorp</city>
        <zip>2571</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Aurum Institute: Pretoria Clinical Research Centre</name>
      <address>
        <city>Pretoria</city>
        <zip>0087</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Aurum Institute: Rustenburg Clinical Research Centre</name>
      <address>
        <city>Rustenberg</city>
        <zip>0300</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Aurum Institute: Tembisa Clinical Research Centre</name>
      <address>
        <city>Tembisa</city>
        <zip>1632</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>https://www.gileadclinicaltrials.com/study/?id=GS-US-412-5624</url>
    <description>Gilead Clinical Trials Website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Emtricitabine tenofovir alafenamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

